NCT07059182View on ClinicalTrials.gov

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 11, 2025

Primary Completion Date

August 29, 2025

Study Completion Date

August 29, 2025

Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASEPrevention of Pneumococcal-induced Acute Otitis Media
Interventions
BIOLOGICAL

Inactivated whole-cell Streptococcus pneumoniae vaccine

Single intramuscular injection of 1 mg protein/0.5 mL wSp vaccine

DRUG

Placebo

Single intramuscular injection of 0.5 mL placebo

Trial Locations (1)

14609

Rochester Clinical Research, Rochester

All Listed Sponsors
lead

Serum Life Science Europe GmbH

INDUSTRY